Payment overview · 2025
General Payments
$727.59
33 reported records · 15 companies
Healthcare provider profile · identity verified
Tharwat A Hanna, MD
Allopathic & Osteopathic Physicians|Internal Medicine · MARSHFIELD, MA · NPI 1205815768
Verified facts
What the public records show
CMS Open Payments records show Tharwat A Hanna, MD received $727.59 in general payments during 2025 across 33 reported records.
AstraZeneca Pharmaceuticals LP accounted for 27.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 19 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Xifaxan.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 35 claims for Jardiance by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Entresto by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 221 claims for Eliquis by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULANCE as an associated drug or biological on 2652 records involving 1501 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Trulance by this doctor in 2024.
Salix Pharmaceuticals, a division of Bausch Health US, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XIFAXAN as an associated drug or biological on 101901 records involving 33018 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Xifaxan by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $197.17 | 27.1% | 8 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $99.47 | 13.7% | 4 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $96.51 | 13.3% | 5 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $59.58 | 8.2% | 3 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $40.55 | 5.6% | 2 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $34.60 | 4.8% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $25.85 | 3.5% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $25.55 | 3.5% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $23.67 | 3.2% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $23.25 | 3.2% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $20.44 | 2.8% | 1 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $20.37 | 2.8% | 1 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $20.37 | 2.8% | 1 | 2025 |
| Becton, Dickinson and Company | Unresolved — no canonical attribution shown | $20.21 | 2.8% | 1 | 2025 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | Unresolved — no canonical attribution shown | $20.00 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $727.59 | 33 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $121.26 | 4 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $99.47 | 4 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $86.85 | 3 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Lundbeck LLC, Otsuka America Pharmaceutical, Inc. | $66.10 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $59.58 | 3 | 2025 |
Source payment records
|
|||||
| PAXLOVID Normalized: paxlovid |
Drug | PFIZER INC. | $52.46 | 3 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $44.05 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $44.05 | 2 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $43.36 | 2 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $34.60 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $34.60 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $25.85 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $23.67 | 1 | 2025 |
Source payment records
|
|||||
| LAGEVRIO Normalized: lagevrio |
Drug | Merck Sharp & Dohme LLC | $23.25 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $20.44 | 1 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $20.37 | 1 | 2025 |
Source payment records
|
|||||
| Sunosi Normalized: sunosi |
Drug | Axsome Therapeutics, Inc. | $20.37 | 1 | 2025 |
Source payment records
|
|||||
| BD Onclarity Normalized: bd onclarity |
Device | Becton, Dickinson and Company | $20.21 | 1 | 2025 |
Source payment records
|
|||||
| XIFAXAN Normalized: xifaxan |
Drug | Salix Pharmaceuticals, a division of Bausch Health US, LLC | $20.00 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 221 | exact normalized | Medicare Part D |
| XIFAXAN xifaxan |
2025 | Xifaxan | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
35 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
22 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
23 | 23 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
221 | 23 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | TRULANCE open payments reported associated product |
CMS Open Payments — General Payments 2652 supporting records · 1501 recipient NPIs · example record 1231775445 |
Trulance · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC Exact reporting entity; no affiliate inference |
2025 | XIFAXAN open payments reported associated product |
CMS Open Payments — General Payments 101901 supporting records · 33018 recipient NPIs · example record 1231775337 |
Xifaxan · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 653 | 124 |
| Trazodone Hcl | Trazodone Hcl | 302 | 36 |
| Levothyroxine Sodium | Levothyroxine Sodium | 250 | 49 |
| Lorazepam | Lorazepam | 250 | 33 |
| Gabapentin | Gabapentin | 246 | 35 |
| Eliquis | Apixaban | 221 | 23 |
| Furosemide | Furosemide | 210 | 24 |
| Oxycodone Hcl | Oxycodone Hcl | 207 | 24 |
| Pantoprazole Sodium | Pantoprazole Sodium | 206 | 34 |
| Alprazolam | Alprazolam | 205 | 32 |
| Tamsulosin Hcl | Tamsulosin Hcl | 198 | 36 |
| Metformin Hcl | Metformin Hcl | 195 | 35 |
| Clonazepam | Clonazepam | 178 | 28 |
| Metoprolol Succinate | Metoprolol Succinate | 177 | 41 |
| Lisinopril | Lisinopril | 173 | 42 |
| Sertraline Hcl | Sertraline Hcl | 151 | 17 |
| Tramadol Hcl | Tramadol Hcl | 148 | 25 |
| Omeprazole | Omeprazole | 138 | 27 |
| Escitalopram Oxalate | Escitalopram Oxalate | 130 | 21 |
| Ibuprofen | Ibuprofen | 121 | 41 |
| Quetiapine Fumarate | Quetiapine Fumarate | 115 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 109 | 30 |
| Divalproex Sodium | Divalproex Sodium | 109 | 11 |
| Metoprolol Tartrate | Metoprolol Tartrate | 106 | 20 |
| Mirtazapine | Mirtazapine | 105 | 16 |
| Risperidone | Risperidone | 105 | 14 |
| Diazepam | Diazepam | 104 | 12 |
| Olanzapine | Olanzapine | 103 | 11 |
| Losartan Potassium | Losartan Potassium | 102 | 20 |
| Amlodipine Besylate | Amlodipine Besylate | 99 | 23 |
| Atenolol | Atenolol | 97 | 22 |
| Lamotrigine | Lamotrigine | 97 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 93 | 20 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 91 | suppressed |
| Simvastatin | Simvastatin | 89 | 25 |
| Xarelto | Rivaroxaban | 89 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 88 | 23 |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 85 | suppressed |
| Glimepiride | Glimepiride | 82 | 15 |
| Januvia | Sitagliptin Phosphate | 81 | suppressed |
| Potassium Chloride | Potassium Chloride | 81 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 75 | 14 |
| Clozapine | Clozapine | 71 | suppressed |
| Famotidine | Famotidine | 68 | suppressed |
| Topiramate | Topiramate | 68 | suppressed |
| Baclofen | Baclofen | 65 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 56 | suppressed |
| Azithromycin | Azithromycin | 55 | 41 |
| Fluoxetine Hcl | Fluoxetine Hcl | 54 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 54 | 13 |
| Citalopram Hbr | Citalopram Hydrobromide | 53 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 52 | suppressed |
| Cephalexin | Cephalexin | 51 | 34 |
| Lansoprazole | Lansoprazole | 49 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 49 | suppressed |
| Finasteride | Finasteride | 47 | suppressed |
| Spironolactone | Spironolactone | 46 | suppressed |
| Pregabalin | Pregabalin | 44 | suppressed |
| Latanoprost | Latanoprost | 41 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 41 | 11 |
| Allopurinol | Allopurinol | 39 | suppressed |
| Levetiracetam | Levetiracetam | 39 | suppressed |
| Benztropine Mesylate | Benztropine Mesylate | 38 | suppressed |
| Jardiance | Empagliflozin | 35 | suppressed |
| Vraylar | Cariprazine Hcl | 35 | suppressed |
| Celecoxib | Celecoxib | 34 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 34 | suppressed |
| Meloxicam | Meloxicam | 34 | suppressed |
| Prednisone | Prednisone | 34 | 18 |
| Ropinirole Hcl | Ropinirole Hcl | 33 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 32 | 11 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 32 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Ezetimibe | Ezetimibe | 31 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 31 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 30 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 30 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 30 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 29 | suppressed |
| Lactulose | Lactulose | 29 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 29 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 28 | suppressed |
| Movantik | Naloxegol Oxalate | 27 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 26 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 26 | 11 |
| Oxycontin | Oxycodone Hcl | 26 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 25 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 24 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 24 | suppressed |
| Memantine Hcl | Memantine Hcl | 24 | suppressed |
| Sucralfate | Sucralfate | 24 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 23 | 23 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 23 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Naproxen | Naproxen | 23 | suppressed |
| Nifedipine Er | Nifedipine | 23 | suppressed |
| Novolin R | Insulin Regular, Human | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 23 | suppressed |
| Phenobarbital | Phenobarbital | 23 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 22 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 22 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Entresto | Sacubitril/Valsartan | 22 | suppressed |
| Erythromycin | Erythromycin Base | 22 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 22 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Motegrity | Prucalopride Succinate | 22 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 22 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 22 | suppressed |
| Clotrimazole | Clotrimazole | 21 | suppressed |
| Methotrexate | Methotrexate Sodium | 21 | suppressed |
| Myrbetriq | Mirabegron | 21 | suppressed |
| Risperidone Er | Risperidone Microspheres | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 20 | suppressed |
| Nystatin | Nystatin | 20 | suppressed |
| Timolol Maleate | Timolol Maleate | 20 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 20 | suppressed |
| Carvedilol | Carvedilol | 19 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 19 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 19 | suppressed |
| Varenicline Tartrate | Varenicline Tartrate | 19 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 18 | suppressed |
| Gemfibrozil | Gemfibrozil | 18 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 17 | suppressed |
| Dorzolamide-Timolol | Dorzolamide Hcl/Timolol Maleat | 17 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 17 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 17 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 16 | suppressed |
| Nyamyc | Nystatin | 16 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 16 | suppressed |
| Sulfasalazine | Sulfasalazine | 16 | suppressed |
| Trintellix | Vortioxetine Hydrobromide | 16 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 15 | suppressed |
| Amoxicillin | Amoxicillin | 15 | suppressed |
| Aripiprazole | Aripiprazole | 15 | suppressed |
| Carisoprodol | Carisoprodol | 15 | suppressed |
| Glipizide | Glipizide | 15 | suppressed |
| Haloperidol | Haloperidol | 15 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 15 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 15 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 14 | suppressed |
| Humulin R | Insulin Regular, Human | 14 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 14 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 14 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 14 | suppressed |
| Phenytoin | Phenytoin | 14 | suppressed |
| Amantadine | Amantadine Hcl | 13 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 13 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 13 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Bupropion Xl | Bupropion Hcl | 13 | suppressed |
| Carbamazepine | Carbamazepine | 13 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 13 | suppressed |
| Creon | Lipase/Protease/Amylase | 13 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 13 | suppressed |
| Ibu | Ibuprofen | 13 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 13 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 13 | suppressed |
| Mupirocin | Mupirocin | 13 | suppressed |
| Novolog | Insulin Aspart | 13 | suppressed |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 13 | suppressed |
| Prednisolone Acetate | Prednisolone Acetate | 13 | suppressed |
| Primidone | Primidone | 13 | suppressed |
| Pyridostigmine Bromide | Pyridostigmine Bromide | 13 | suppressed |
| Testosterone | Testosterone | 13 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 13 | suppressed |
| Xifaxan | Rifaximin | 13 | suppressed |
| Albuterol Sulfate | Albuterol Sulfate | 12 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 12 | suppressed |
| Chlorpromazine Hcl | Chlorpromazine Hcl | 12 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 12 | suppressed |
| Janumet | Sitagliptin Phos/Metformin Hcl | 12 | suppressed |
| Modafinil | Modafinil | 12 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 12 | suppressed |
| Prempro | Estrogen,con/M-Progest Acet | 12 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 12 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 12 | suppressed |
| Valproic Acid | Valproic Acid | 12 | suppressed |
| Acyclovir | Acyclovir | 11 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 11 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 11 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 11 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 11 | suppressed |
| Restasis | Cyclosporine | 11 | suppressed |
| Semglee (Yfgn) Pen | Insulin Glargine-Yfgn | 11 | suppressed |
| Trulance | Plecanatide | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $727.59 · 33 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BD Onclarity, BREZTRI, CAPLYTA, DAYBUE, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, IBSRELA, LAGEVRIO, LEQVIO, MOUNJARO, NURTEC ODT, PAXLOVID, REXULTI, Sunosi, Wegovy, XIFAXAN, ZEPBOUND | 6 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Lilly USA, LLC?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error